Bolt Biotherapeutics

Bolt Biotherapeutics Inventory

The Inventory of Bolt Biotherapeutics (BOLT) as of Nov 20, 2026 is 1.00 USD. In the previous year, Inventory was -800,000.00 USD — a change of -100.00% (higher).

Inventory

1.00USD

YoY

-100.00%

Last updated:

Inventory of Bolt Biotherapeutics is 2024 1.00 USD. Inventory of Bolt Biotherapeutics was 2023 -800,000.00 USD. It decreases by -100.00% higher compared to the previous year.

The Bolt Biotherapeutics Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2019
-300,000.00 USD
Jan 1, 2020
-12,000.00 USD
Jan 1, 2021
-200,000.00 USD
Jan 1, 2022
-800,000.00 USD
Jan 1, 2024
1.00 USD
The Bolt Biotherapeutics Inventory history
YEARInventoryYoY
1.00USD-100.00%
-800,000.00USD+300.00%
-200,000.00USD+1,566.67%
-12,000.00USD-96.00%
-300,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bolt Biotherapeutics Stock analysis

What does Bolt Biotherapeutics do? Bolt Biotherapeutics, Inc. develops immunotherapies for cancer treatment using its proprietary Boltbody ISAC platform, which combines tumor-targeting antibodies with immune-stimulating linker payloads. The company's first product, BDC-1001, targets HER2 and has completed dose-escalation trials, advancing into Phase II studies. BDC-3042, a Dectin-2 agonist antibody program, aims to repolarize tumor-associated macrophages in the tumor microenvironment. The company generates revenue through clinical development and potential future commercialization of its therapies, focusing on oncology indications. Bolt Biotherapeutics targets the biopharmaceutical sector with its novel immunotherapy platform, primarily engaging in research and development of cancer treatments. Its products are designed to work with the patient's immune system to create anti-cancer efficacy with tolerability. The company's clinical-stage development of BDC-1001 and BDC-3042 positions it for potential partnerships or licensing deals with pharmaceutical companies seeking innovative oncology solutions. The company's revenue model relies on the progression of its clinical programs toward regulatory approval and eventual market entry. BDC-1001 and BDC-3042 are being developed for specific cancer indications, with BDC-1001 targeting HER2-positive cancers and BDC-3042 focusing on tumor microenvironment modulation. Bolt Biotherapeutics may secure funding through partnerships, grants, or future product sales once clinical trials demonstrate efficacy and safety. Bolt Biotherapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bolt Biotherapeutics stock

Inventory of Bolt Biotherapeutics is 1.00 USD in 2024.

Inventory of Bolt Biotherapeutics changed from -800,000.00 USD to 1.00 USD, representing a -100.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory Bolt Biotherapeutics since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Bolt Biotherapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bolt Biotherapeutics

All Key Metrics — Bolt Biotherapeutics